CollPlant Biotechnologies (CLGN) investor relations material

Company overview and business model

• Focuses on regenerative and aesthetic medicine, leveraging proprietary recombinant human collagen (rhCollagen) produced in genetically engineered tobacco plants for medical aesthetics and 3D bioprinting of tissues and organs.

• Product pipeline includes a photocurable regenerative dermal filler, 3D-bioprinted breast implants, and commercially available rhCollagen-based bioinks for tissue engineering.

• Recent developments include the termination of a development and commercialization agreement with Allergan (AbbVie), leading to a strategic shift toward new partnerships and a significant cost-reduction plan, including a 50% workforce reduction.

Financial performance and metrics

• As of December 31, 2025, shareholders' equity was $6.08 million, with pro forma as adjusted equity of $13.63 million after the February 2026 offering.

• The February 2026 offering raised approximately $1.7 million in net proceeds, with a potential additional $4.15 million if all private placement warrants are exercised for cash.

• The company has a history of significant losses and faces substantial doubt about its ability to continue as a going concern.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by selling shareholders; proceeds from warrant exercises (if any) will be used for general corporate purposes, including working capital and R&D.

• Pending use, any proceeds from warrant exercises will be invested in bank deposits.